Dasatinib-induced nephrotic syndrome

Leuk Lymphoma. 2016;57(3):726-7. doi: 10.3109/10428194.2015.1075020. Epub 2015 Oct 5.

Authors

Taichi Hirano¹, Miyuki Hashimoto², Yu Korogi², Takahiro Tsuji¹, Kei Miyanaka², Hiroshi Yamasaki¹, Hiroyuki Tsuda¹

Affiliations

¹ a Department of Hematology and Oncology and.
² b Department of Nephrology , Kumamoto City Hospital , Higashi-ward, Kumamoto , Japan.

PMID: 26436329
DOI: 10.3109/10428194.2015.1075020

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dasatinib / administration & dosage
Dasatinib / adverse effects*
Female
Humans
Middle Aged
Nephrotic Syndrome / diagnosis*
Nephrotic Syndrome / etiology*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Dasatinib